In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

GLP-1 and its analogs (such as semaglutide, liraglutide, and dulaglutide) have rapidly become cornerstone treatments for type 2 diabetes mellitus (T2DM) and obesity. These drugs are effective in ...

Semaglutide, the active ingredient in these drugs, is the latest in this class of GLP-1 agonists. Liraglutide (Saxenda) has been on the market for years, but it did not generate the same kind of ...

GLP-1 drugs are already a success story, making Novo Nordisk, maker of Wegovy and Ozempic, until recently Europe’s highest valued company. However, it appears that the sector is only just getting ...

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. They were originally developed to treat type 2 diabetes, which happens ...

rising at a CAGR of 6.3% The market is categorized by drug type into GLP-1 receptor agonists and DPP-4 inhibitors, with a market size of USD 35.5 billion in 2023. The rising demand for GLP-1 receptor ...

“I think there’s a strong linkage between the initial phase of using this medication ... “Even though the GLP-1 drug classes have created hype, I don’t think we should forget some of ...

LITTLE ROCK (KATV) — GLP-1 drugs are making waves in the world of weight loss and health management, but what exactly are they? Allison Debussy, an APRN with Baptist Health Weight Loss Center ...